Kohei Shitara, MD, National Cancer Center Hospital East, Chiba, Japan, provides an overview of findings from the Phase III SPOTLIGHT trial (NCT03504397), which assessed zolbetuximab in patients with CLDN18.2-positive, HER2-negative, locally advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. Zolbetuximab is a first-in-class monoclonal antibody targeting CLDN18.2, and patients were given modified-FOLFOX6 with or without zolbetuximab. 2735 patients were recruited, and addition of zolbetuximab significantly improved progression-free survival and overall survival. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
